BIOPOWERTECH

Basic Information

BIOPOWERTECH
4734 BLUEGRASS PKY
TUSCALOOSA, AL, 35406 4040

Company Profile

n/a

Additional Details

Field Value
DUNS: 603569331
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: Y
Number of Employees: n/a


  1. A novel biomarker of infection in neutropenic cancer patients

    Amount: $311,003.00

    DESCRIPTION provided by applicant Early diagnosis of an infection in neutropenic cancer patients is critical for timely treatment But the diagnosis of an infection in these patients especially at ...

    SBIR Phase I 2015 Department of Health and Human Services National Institutes of Health
  2. Development of recombinant rhTL1A protein for cancer treatment

    Amount: $329,560.00

    DESCRIPTION (provided by applicant): Breast cancer is the most common cause of cancer in women and the second most common cause of cancer death in women in the United States. In 2009, approximately 40 ...

    SBIR Phase I 2010 Department of Health and Human Services
  3. Targeting Deceoy Receptor 3 in Breast Cancer

    Amount: $335,322.00

    DESCRIPTION (provided by applicant): Breast cancer is the leading cause of cancer deaths in the United States. In this year alone, approximately 40,480 women in the US are estimated to die from breast ...

    SBIR Phase I 2008 Department of Health and Human Services
  4. Development of immunoassay to measure a novel TNF-like protein

    Amount: $115,389.00

    DESCRIPTION (provided by applicant): The tumor necrosis factor (TNF) family cytokines (ligands) mediate diverse immune responses via the activation of their cognate receptors expressed on the cell sur ...

    SBIR Phase I 2007 Department of Health and Human Services
  5. A novel therapy for sepsis

    Amount: $203,439.00

    Description: (Provided by Applicant) Sepsis a serious life-threatening condition resulting from a harmful inflammatory reaction of the body due to bacterial infection. The mortality rate of sepsis rem ...

    SBIR Phase I 2007 Department of Health and Human Services
  6. Decoy receptor 3 and liver cirrhosis

    Amount: $109,681.00

    DESCRIPTION (provided by applicant): Liver cirrhosis is a chronic and degenerative disease that can lead to inability of the liver to perform its biochemical function thus severely affecting the quali ...

    SBIR Phase I 2006 Department of Health and Human Services
  7. A therapeutic potential of soluble decoy receptor 3 in sepsis

    Amount: $112,572.00

    DESCRIPTION (provided by applicant): Sepsis a serious life-threatening condition resulting from a harmful inflammatory reaction of the body due to bacterial infection. The mortality rate of sepsis re ...

    SBIR Phase I 2006 Department of Health and Human Services
  8. Soluble Decoy Receptor 3 in Bacterial Infection and Sepsis

    Amount: $107,000.00

    DESCRIPTION (provided by applicant): Sepsis is a serious inflammatory reaction of the body due to bacterial infection, and the mortality rate of severe sepsis is high in intensive care units around th ...

    SBIR Phase I 2006 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government